Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)

Summary

Phase 2/3 randomized, parallel group, 2-arm study (treatment vs. control), investigating the efficacy and safety of intravenous administration of anakinra, an interleukin 1 receptor antagonist ( IL-1), added to standard treatment, compared to standard treatment alone, to reduce hyperinflammation and respiratory distress in patients with SARS-CoV-2 infection.

Timeline

Start

2020-05-08

Primary completion

2021-03-31

Completion

2021-03-31

Publications

• Fanlo P, Gracia-Tello BDC, Fonseca Aizpuru E, Alvarez-Troncoso J, Gonzalez A, Prieto-Gonzalez S, Freire M, Argibay AB, Pallares L, Todoli JA, Perez M, Bujan-Rivas S, Ibanez B; GEAS-SEMI Group. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial. JAMA Netw Open. 2023 Apr 3;6(4):e237243. doi: 10.1001/jamanetworkopen.2023.7243.

Drugs

Indications